Altimmune, Inc. (ALT) Balance Sheet

NASDAQ: ALTAssets, liabilities, debt and equity over 10 years.

ALT balance sheet, 2025

December 31, 2025 · U.S. dollars

$279.9M assets = $55.0M liabilities + $224.9M equity

What it owns$279.9MCash & ST investments: $273.5M (97.7%)Cash & ST investments$273.5M · 98%Receivables: $1.7M (0.6%)Other current: $3.0M (1.1%)PP&E: $312,000 (0.1%)Other non-current: $1.4M (0.5%)=How it is financed$279.9MCurrent liabilities: $15.0M (5.4%)Long-term debt: $34.3M (12.2%)Long-term debt$34.3M · 12%Other LT liabilities: $5.8M (2.1%)Shareholders’ equity: $224.9M (80.3%)Shareholders’ equity$224.9M · 80%

Both columns are drawn to the same scale: what ALT owns equals what it owes plus shareholders’ equity. Hover a block for its value.

ALT financial health

Debt / equity0.16
Low leverage · $0.16 of debt for each $1 of equity
Equity / assets80.3%
Equity-funded · of assets funded by shareholders
Cash / debt766.2%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

ALT balance sheet trends, 2016–2025

Altimmune, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$224.7M2016$279.9M2025+2.5%/yr
Total liabilities$205.3M2016$55.0M2025−13.6%/yr
Shareholders’ equity$19.5M2016$224.9M2025+31.2%/yr
Cash & short-term investments$220.8M2016$273.5M2025+2.4%/yr
Total debt$2.0M2016$35.7M2025+37.8%/yr
Net cash (debt)$218.8M2016$237.8M2025+$19.0M
Working capital$17.4M2016$263.2M2025+$245.8M
Book value per share$4.822021$2.552025−14.7%/yr
Debt / equity0.1020160.162025+0.06
Shares outstanding41.3M202188.1M2025+20.9%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

ALT assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

ALT liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

ALT debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

ALT balance sheet

Altimmune, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$273.5M$131.9M$197.8M$184.9M$190.3M$215.9M$37.2M$33.7M$8.8M$220.8M
Cash & equivalents$43.8M$36.9M$135.1M$111.1M$190.3M$115.9M$9.0M$33.7M$8.8M$154.0M
Short-term investments$229.7M$95.0M$62.7M$73.8M$0$100.0M$28.3M—$3.5M$66.8M
Receivables$1.7M$3.1M$4.9M$2.5M$5.8M$12.4M$1.7M$4.5M$10.2M$999,145
Inventory$0$0$0$34,000−$13.39B−$1.96B−$503.9M$0$3.5M$0
Other current assets$3.0M$2.2M$7.0M$5.4M$13.40B$1.96B$504.4M$1.2M$994,332$464,797
Total current assets$278.2M$137.3M$209.6M$192.8M$204.1M$230.3M$39.4M$39.4M$23.5M$222.3M
Property, plant & equipment (net)$312,000$413,000$651,000$1.1M$1.4M$2.0M$1.8M$1.3M$603,146$120,944
Goodwill & intangible assets$0$0$0$12.4M$12.4M$12.8M$12.7M$13.9M$38.7M$17.3M
Long-term investments$0$0$0$0$0$0$0$0$0$0
Other non-current assets$1.4M$1.6M$363,000$615,000$871,976$73,413$128,547$183,682$238,917$0
Total assets$279.9M$139.3M$210.6M$206.9M$218.9M$245.1M$54.1M$54.8M$63.0M$224.7M
Liabilities
Accounts payable$2.7M$211,000$2.1M$4.8M$2.0M$612,293$18,232$372,860$129,075$926,529
Short-term debt$256,000$279,000$496,000$452,000$411,450$356,716$259,449$71,596$49,702$1.5M
Deferred revenue——$1—$9.7M$19,753$61,563$19,753$19,753$19,753
Total current liabilities$15.0M$10.5M$12.1M$17.1M$18.3M$12.0M$3.9M$4.5M$3.8M$204.8M
Long-term debt$34.3M$0$0$0$1.5M$1.8M$1.9M$1.9M$4.6M$525,950
Lease obligations$1.4M$1.7M$671,000$1.1M$1.5M$1.8M$1.7M———
Other long-term liabilities$5.8M$5.3M$4.4M$4.6M$0$5.4M$2.8M$58,500$5.9M$0
Total liabilities$55.0M$15.8M$16.5M$21.6M$19.7M$19.2M$8.5M$6.4M$14.4M$205.3M
Shareholders' equity
Common stock & paid-in capital$11,000$7,000$7,000$5,000$4,090$3,697$1,508$876$1,810$6,773
Retained earnings (deficit)−$649.5M−$561.4M−$466.3M−$377.9M−$293.2M−$186.4M−$137.4M−$116.9M−$77.7M−$29.9M
Treasury stock————————$0$0
Accumulated other comprehensive income−$4.9M−$5.0M−$5.0M−$5.2M−$5.0M−$5.0M−$5.0M−$5.0M−$4.6M−$1,052
Minority interest————————$0$0
Total shareholders' equity$224.9M$123.5M$194.1M$185.3M$199.1M$225.9M$45.5M$48.3M$48.7M$19.5M
Key figures
Total debt$35.7M$1.7M$671,000$1.1M$1.9M$2.2M$2.1M$1.9M$4.6M$2.0M
Net cash (debt)$237.8M$130.2M$197.1M$183.8M$188.4M$213.7M$35.1M$31.8M$4.1M$218.8M
Working capital$263.2M$126.8M$197.5M$175.8M$185.9M$218.2M$35.5M$34.8M$19.6M$17.4M
Tangible book value$224.9M$123.5M$194.1M$172.9M$186.7M$213.1M$32.8M$34.5M$10.0M$2.2M
Book value per share$2.55$1.74$3.65$3.95$4.82—————
Shares outstanding88.1M71.0M53.2M46.9M41.3M—————
Current ratio18.5513.1117.2611.3111.1719.1610.048.706.111.09
Quick ratio18.3512.9016.6910.9910.7318.999.918.444.931.08
Debt / equity0.160.010.000.010.010.010.050.040.090.10
Equity / assets80.3%88.7%92.1%89.5%91.0%92.2%84.2%88.2%77.2%8.7%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 6, 2026); data from EODHD.

ALT financial position

At the end of fiscal 2025 (December 31, 2025), Altimmune had total assets of $279.9 million (up 100.9% from a year earlier), total liabilities of $55.0 million and shareholders' equity of $224.9 million. It held $273.5 million in cash and short-term investments against $35.7 million of debt, a net cash position of $237.8 million. Its current ratio was 18.55. In the latest quarter (ended June 30, 2026) total assets were $527.2 million and equity $474.2 million.

Related: ALT income statement, ALT cash flow statement, ALT key metrics. See the ALT stock overview for the latest quote and news.

ALT balance sheet FAQ

What are Altimmune's total assets?

Altimmune reported total assets of $279.9 million at the end of fiscal 2025 (December 31, 2025), compared with $139.3 million a year earlier.

How much debt does Altimmune have?

Altimmune had $35.7 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.16.

How much cash does Altimmune have?

Altimmune held $273.5 million in cash and short-term investments at the end of fiscal 2025; with $35.7 million of debt that is net cash of $237.8 million.

What is Altimmune's book value?

Altimmune's shareholders' equity (book value) was $224.9 million at the end of fiscal 2025, or $2.55 per share.

What is Altimmune's current ratio?

Altimmune had current assets of $278.2 million and current liabilities of $15.0 million, a current ratio of 18.55 (it can cover its short-term obligations).

Biotechnology: balance sheet